ALSO NOTED: Serono files sBLA for Rebif; Germany's Ingenium raises €9.2M in VC; and much more...

> Switzerland's Serono has filed a supplemental BLA for a new formulation of its MS drug Rebif. According to Phase III data, the new formulation is more easily tolerated by patients. Report

> Achillion Pharmaceuticals has filed for a $75 million IPO. Report

> Germany's Ingenium has raised €9.2 million in its fourth round of venture capital. Release

> Unhappy Chiron shareholders were won over by Novartis' newly sweetened bid offer, paving the way for a merger. Report

> The FDA has granted a priority review for Avanir Pharmaceuticals' Neurodex, a drug for under-treated emotional disorder. Report

> The FDA has granted priority review for Remicade as a treatment for pediatric Crohn's disease. Report

> Chutes & Ladders: SIGA Technologies' CEO Kasten Bernard has resigned. Report

> Canada's Bioniche Life Sciences announced that the FDA has given its approval for a second Phase III trial of an experimental bladder cancer therapy. Article

> ArQule is reporting positive Phase I data for ARQ501, its lead cancer therapy. Release

> Halozyme Therapeutics says that preclinical and Phase I data for Chemophase supported the safety profile of the enzyme-chemo combination for bladder cancer. Release

> Biosite and Oxford Genome Sciences have announced a collaboration to evaluate protein-based disease markers for colorectal cancer. Release

> In a preclinical data presentation Antisoma said that data showed that a combination of its AS1404 and Avastin performed markedly better than Avastin alone in inhibiting the growth of human colon and lung tumour xenografts. Release

And Finally... California plays a leading role in the spread of influenza, and researchers are struggling to find out why. Article